Picture of Takeda Pharmaceutical Co logo

TAK Takeda Pharmaceutical Co News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapNeutral

REG - Societe Generale SA Takeda Pharma.Co.Ltd - Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD





 




RNS Number : 4515Z
Societe Generale SA
31 August 2018
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1.         KEY INFORMATION

 

(a) Full name of discloser:

Société Générale S.A.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.

 

 

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

     Use a separate form for each offeror/offeree

Takeda Pharmaceutical CO LTD

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:


(e) Date position held/dealing undertaken:

     For an opening position disclosure, state the latest practicable date prior to the disclosure

30/08/2018

(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

     If it is a cash offer or possible cash offer, state "N/A"

YES: Shire PLC

 

 

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary

 

 

Interests

Short positions


Number

%

Number

%

(1) Relevant securities owned and/or controlled:

1,686,877

0.22

6,259,741

0.80

(2) Cash-settled derivatives:

 

5,041,202

0.64

2,026

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

121,500

0.02

0

0.00

 

     TOTAL:

6,849,579

0.87

6,261,767

0.80

           

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b)        Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:


Details, including nature of the rights concerned and relevant percentages:


 

 

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

JPY

Ordinary

Purchase

1,200

4622

Ordinary

Purchase

300

4619

Ordinary

Purchase

500

4625

Ordinary

Purchase

1,500

4606

Ordinary

Purchase

2,000

4605

Ordinary

Purchase

100

4618

Ordinary

Purchase

500

4620

Ordinary

Purchase

400

4620

Ordinary

Purchase

900

4607

Ordinary

Purchase

100

4623

Ordinary

Purchase

1,300

4626

Ordinary

Purchase

100

4610

Ordinary

Purchase

400

4605

Ordinary

Purchase

2,800

4600

Ordinary

Purchase

10,200

4630

Ordinary

Purchase

300

4634

Ordinary

Purchase

300

4596

Ordinary

Purchase

1,000

4622

Ordinary

Purchase

300

4620

Ordinary

Purchase

800

4617

Ordinary

Purchase

100

4619

Ordinary

Purchase

1,000

4606

Ordinary

Purchase

200

4626

Ordinary

Purchase

400

4609

Ordinary

Purchase

700

4605

Ordinary

Purchase

500

4607

Ordinary

Purchase

200

4609

Ordinary

Purchase

1,800

4612

Ordinary

Purchase

1,000

4605

Ordinary

Purchase

1,000

4627

Ordinary

Purchase

1,000

4609

Ordinary

Purchase

1,000

4611

Ordinary

Purchase

500

4608

Ordinary

Purchase

200

4608

Ordinary

Purchase

1,000

4623

Ordinary

Purchase

300

4626

Ordinary

Purchase

500

4626

Ordinary

Purchase

500

4599

Ordinary

Purchase

300

4601

Ordinary

Purchase

100

4603

Ordinary

Purchase

2,400

4600

Ordinary

Purchase

10,300

4600

Ordinary

Purchase

1,100

4600

Ordinary

Purchase

94

4594

Ordinary

Purchase

25

4560

Ordinary

Sale

1,400

4611

Ordinary

Sale

2,000

4606

Ordinary

Sale

300

4611

Ordinary

Sale

900

4626

Ordinary

Sale

1,000

4610

Ordinary

Sale

2,200

4604

Ordinary

Sale

400

4604

Ordinary

Sale

1,500

4624

Ordinary

Sale

400

4601

Ordinary

Sale

700

4599

Ordinary

Sale

900

4600

Ordinary

Sale

200

4616.5

Ordinary

Sale

100

4615.5

Ordinary

Sale

300

4606

Ordinary

Sale

100

4613

Ordinary

Sale

200

4615

Ordinary

Sale

100

4603.5

Ordinary

Sale

100

4612

Ordinary

Sale

100

4612

Ordinary

Sale

100

4627

Ordinary

Sale

100

4629

Ordinary

Sale

100

4629

Ordinary

Sale

100

4610

Ordinary

Sale

100

4601

Ordinary

Sale

100

4620

Ordinary

Sale

600

4602

Ordinary

Sale

1,000

4612

Ordinary

Sale

1,000

4602

Ordinary

Sale

100

4622

Ordinary

Sale

62,925

4612.1383

Ordinary

Sale

69

4660


Total Purchases

51,219



Total Sales

79,194


 

(b)        Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit JPY

Ordinary

CFD

Increasing a long position

62,925

4612.1383

 

 (c)       Stock-settled derivative transactions (including options)

 

(i)         Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit JPY









 

(ii)        Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit JPY





 

 

 

(d)        Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable) JPY


 

 



4.         OTHER INFORMATION

 

(a)        Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b)        Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i)  the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c)        Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES

 

 

Date of disclosure:

31/08/2018

Contact name:

Olivier Vero

Telephone number:

+44 20 7676 6969

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk

 

 

 



SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

 

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

 

 

1.         KEY INFORMATION

 

Full name of person making disclosure:

SOCIETE GENERALE SA

Name of offeror/offeree in relation to whose relevant securities the disclosure relates:

Takeda Pharmaceutical CO LTD

 

2.         STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

 

 

Class of relevant security

Product description e.g. call option

Written or purchased

Number of securities to which option or derivative relates

Exercise price per unit

Type

Expiry date

JPY

e.g. American, European etc.

Ordinary

OTC put-option

Sale

15,700

4707

European options

14/12/2018

Ordinary

OTC put-option

Sale

30,000

5075.10

European options

14/12/2018

Ordinary

OTC put-option

Sale

29,600

5073.65

European options

14/12/2018

Ordinary

OTC put-option

Sale

15,500

4491.40

European options

14/12/2018

Ordinary

OTC put-option

Sale

30,700

4533.90

European options

14/12/2018

 

 

 

3.         AGREEMENTS TO PURCHASE OR SELL ETC.

 

Full details should be given so that the nature of the interest or position can be fully understood:

 

 

 

 

 

 

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.

 

The currency of all prices and other monetary amounts should be stated.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETWGUAGRUPRGWG

Recent news on Takeda Pharmaceutical Co

See all news